Vanda Prescribed drugs (VNDA) got here out with a quarterly lack of $0.38 per share versus the Zacks Consensus Estimate of a lack of $0.31. This compares to a lack of $0.09 per share a 12 months in the past. These figures are adjusted for non-recurring objects.
This quarterly report represents an earnings shock of -22.58%. 1 / 4 in the past, it was anticipated that this biopharmaceutical firm would put up a lack of $0.34 per share when it really produced a lack of $0.46, delivering a shock of -35.29%.
Over the past 4 quarters, the corporate has surpassed consensus EPS estimates two instances.
Vanda, which belongs to the Zacks Medical – Biomedical and Genetics business, posted revenues of $56.26 million for the quarter ended September 2025, lacking the Zacks Consensus Estimate by 6.24%. This compares to year-ago revenues of $47.65 million. The corporate has topped consensus income estimates two instances during the last 4 quarters.
The sustainability of the inventory’s fast value motion primarily based on the recently-released numbers and future earnings expectations will principally depend upon administration’s commentary on the earnings name.
Vanda shares have added about 16.5% because the starting of the 12 months versus the S&P 500’s acquire of 17.2%.
What’s Subsequent for Vanda?
Whereas Vanda has underperformed the market thus far this 12 months, the query that involves buyers’ minds is: what’s subsequent for the inventory?
There are not any simple solutions to this key query, however one dependable measure that may assist buyers deal with that is the corporate’s earnings outlook. Not solely does this embrace present consensus earnings expectations for the approaching quarter(s), but additionally how these expectations have modified currently.
Empirical analysis exhibits a robust correlation between near-term inventory actions and developments in earnings estimate revisions. Buyers can monitor such revisions by themselves or depend on a tried-and-tested ranking device just like the Zacks Rank, which has a powerful monitor file of harnessing the facility of earnings estimate revisions.
Forward of this earnings launch, the estimate revisions development for Vanda was blended. Whereas the magnitude and path of estimate revisions may change following the corporate’s just-released earnings report, the present standing interprets right into a Zacks Rank #3 (Maintain) for the inventory. So, the shares are anticipated to carry out in step with the market within the close to future. You possibly can see the whole listing of at present’s Zacks #1 Rank (Sturdy Purchase) shares right here.
It will likely be attention-grabbing to see how estimates for the approaching quarters and the present fiscal 12 months change within the days forward. The present consensus EPS estimate is -$0.20 on $64 million in revenues for the approaching quarter and -$1.75 on $226.63 million in revenues for the present fiscal 12 months.
Buyers must be aware of the truth that the outlook for the business can have a cloth impression on the efficiency of the inventory as nicely. By way of the Zacks Trade Rank, Medical – Biomedical and Genetics is at present within the high 37% of the 250 plus Zacks industries. Our analysis exhibits that the highest 50% of the Zacks-ranked industries outperform the underside 50% by an element of greater than 2 to 1.
One different inventory from the identical business, VistaGen Therapeutics, Inc. (VTGN), is but to report outcomes for the quarter ended September 2025.
This firm is predicted to put up quarterly lack of $0.51 per share in its upcoming report, which represents a year-over-year change of -21.4%. The consensus EPS estimate for the quarter has been revised 11.1% increased during the last 30 days to the present stage.
VistaGen Therapeutics, Inc.’s revenues are anticipated to be $0.63 million, up 250% from the year-ago quarter.
Ought to You Spend money on Vanda Prescribed drugs Inc. (VNDA)?
Earlier than you spend money on Vanda Prescribed drugs Inc. (VNDA), wish to know the most effective shares to purchase for the subsequent 30 days? Take a look at Zacks Funding Analysis for our free report on the 7 finest shares to purchase.
Zacks Funding Analysis has been dedicated to offering buyers with instruments and impartial analysis since 1978. For greater than 1 / 4 century, the Zacks Rank stock-rating system has greater than doubled the S&P 500 with a median acquire of +24.08% per 12 months. (These returns cowl a interval from January 1, 1988 by way of Might 6, 2024.)
Vanda Prescribed drugs Inc. (VNDA) : Free Inventory Evaluation Report
VistaGen Therapeutics, Inc. (VTGN) : Free Inventory Evaluation Report
This text initially revealed on Zacks Funding Analysis (zacks.com).
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially replicate these of Nasdaq, Inc.
